

preventing infections in healthcare settings. The guideline replaces the Guideline for Prevention of Nosocomial Pneumonia, published in 1994.

DATES: Comments on the Draft Guideline for Prevention of Healthcare-associated Pneumonia, 2003, must be received in writing on or before October 18, 2002.

FOR FURTHER INFORMATION CONTACT:

Requests for copies of the Draft Guideline for Prevention of Healthcare-associated Pneumonia, 2003, should be submitted to the Resource Center, Attention: PNGuide, Division of Healthcare Quality Promotion, CDC, Mailstop E-68, 1600 Clifton Rd., NE, Atlanta, Georgia 30333; fax 404 498-1244; e-mail: pnrequests@cdc.gov; or Internet: www.cdc.gov/ncidod/hip/pnguide.htm.

ADDRESSES: Comments on the Draft Guideline for Prevention of Healthcare-associated Pneumonia, 2003, should be submitted to the Resource Center, Attention: PNGuide, Division of Healthcare Quality Promotion, CDC, Mailstop E-68, 1600 Clifton Road, NE, Atlanta, Georgia 30333; fax 404 498-1244; e-mail: pncomments@cdc.gov; or Internet: www.cdc.gov/ncidod/hip/pnguide.htm.

SUPPLEMENTARY INFORMATION: The Draft Guideline for Prevention of Healthcare-associated Pneumonia, 2003, addresses the prevention and control of healthcare-associated bacterial pneumonia, especially ventilator-associated pneumonia; Legionnaire's disease; pertussis; invasive pulmonary aspergillosis; viral pneumonia; respiratory syncytial virus infection; parainfluenza; adenovirus infection; and influenza. Part I discusses the epidemiology, diagnosis, pathogenesis, modes of transmission, and prevention and control of the diseases listed above. Part II contains the consensus recommendations of the Healthcare Infection Control Practices Advisory Committee (HICPAC) and addresses such issues as education of healthcare personnel regarding the prevention and control of healthcare-associated pneumonia and other lower respiratory tract diseases and measures to prevent person-to-person transmission of each disease.

HICPAC was established in 1991 to provide advice and guidance to the Secretary and the Assistant Secretary for Health, DHHS; the Director, CDC; and the Director, National Center for Infectious Diseases, regarding the practice of infection control and strategies for surveillance, prevention, and control of healthcare-associated

infections in U.S. healthcare facilities. The committee advises CDC on guidelines and other policy statements regarding prevention of healthcare-associated infections and related adverse events.

Dated: August 27, 2002.

James D. Seligman,

Associate Director for Program Services, Centers for Disease Control and Prevention.

[FR Doc. 02-22309 Filed 8-30-02; 8:45 am]

BILLING CODE 4163-18-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Administration for Children and Families

President's Committee on Mental Retardation; Notice of Meeting

AGENCY: President's Committee on Mental Retardation (PCMR).

ACTION: Notice of meeting.

DATES: Monday, September 23, 2002, from 8 a.m. to 5 p.m., and Tuesday, September 24, 2002, from 8 a.m. to 11 a.m. The entire meeting of the President's Committee on Mental Retardation will be open to the public.

ADDRESSES: The meeting will be held at the Indian Treaty Room, Old Executive Office Building, 17th Street and Pennsylvania Avenue, Washington, DC 20500. Enter the building at the Pennsylvania Avenue entrance and be prepared to show a photo ID. Please allow extra time for security procedures. It will be necessary for all persons planning to enter the Old Executive Office Building to provide their name, date of birth and social security number no later than September 13, 2002, to the Executive Director, President's Committee on Mental Retardation (*see* below for contact information). A barrier free entrance is available to the Old Executive Office Building at its 17th and G Streets, NW., entrance. The same security requirements apply for that entrance.

Agenda: The Committee plans to discuss critical issues concerning President George W. Bush's New Freedom Initiative, inter-agency collaboration and cooperation, and removal of barriers to full community integration and improved quality of life for individuals with mental retardation. An interpreter for the deaf will be available upon request.

FOR FURTHER INFORMATION CONTACT: Sally Atwater, President's Committee on Mental Retardation, Room 701, Aerospace Building, 370 L'Enfant Promenade, SW., Washington, DC

20447, telephone—(202) 619-0634, fax—(202) 205-9519, e-mail—satwater@acf.hhs.gov.

SUPPLEMENTARY INFORMATION: The PCMR acts in an advisory capacity to the President and the Secretary of the U.S. Department of Health and Human Services on a broad range of topics relating to programs, services and support for persons with mental retardation. The Committee is responsible for evaluating the adequacy of current practices in programs and support for person with mental retardation, and for reviewing legislative proposals that impact the quality of life that is experienced by citizens with mental retardation and their families. The Committee submits an annual report to the President.

Dated: August 26, 2002.

Sally Atwater,

Executive Director, President's Committee on Mental Retardation.

[FR Doc. 02-22318 Filed 8-30-02; 8:45 am]

BILLING CODE 4184-01-M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Substance Abuse and Mental Health Services Administration

Current List of Laboratories Which Meet Minimum Standards To Engage in Urine Drug Testing for Federal Agencies

AGENCY: Substance Abuse and Mental Health Services Administration, HHS.

ACTION: Notice.

SUMMARY: The Department of Health and Human Services notifies Federal agencies of the laboratories currently certified to meet standards of subpart C of Mandatory Guidelines for Federal Workplace Drug Testing Programs (59 FR 29916, 29925). A notice listing all currently certified laboratories is published in the **Federal Register** during the first week of each month. If any laboratory's certification is suspended or revoked, the laboratory will be omitted from subsequent lists until such time as it is restored to full certification under the Guidelines.

If any laboratory has withdrawn from the National Laboratory Certification Program during the past month, it will be listed at the end, and will be omitted from the monthly listing thereafter.

This notice is also available on the internet at the following websites: <http://workplace.samhsa.gov> and <http://www.drugfreeworkplace.gov>.

FOR FURTHER INFORMATION CONTACT: Mrs. Giselle Hersh or Dr. Walter Vogl,